Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMP013/ALFQ Malaria Vaccine in Healthy Malaria-Naïve Adults
NCT04268420Phase 1Unknown
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Mar 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FMP013 in malaria (6 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Safety Dosage of Candidate Malaria Vaccine FMP013/ALFQ at 393 days and Assess Reactogenicity of Candidate Malaria Vaccine FMP013/ALFQ at 393 days. Status: unknown.
02
Drugs
FMP013
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04268420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268420.